Macroaxis LLC

Stock correlation table for December 2024: NRG Energy( $NRG ), WEC Energy( $WEC ), Consolidated Edison( $ED ), AGNC Investment( $AGNC ), Halliburton( $HAL ), Genworth Financial( $GNW ), F5 Networks( $FFIV ), Exicure( $XCUR ), Xtrackers California( $CA ), Western Union( $WU ), CME( $CME ) and Gannett( $GCI ) https://lnkd.in/gTnJSvib #correlations #stocks #stockratings

Check this portfolio in December 2024: Akamai Technologies( $AKAM ), T Rowe( $TROW ), Affiliated Managers( $AMG ), Chipotle Mexican( $CMG ), Corning Incorporated( $GLW ), Synnex( $SNX ), Perrigo Company( $PRGO ), Eastman Chemical( $EMN ), Cardinal Health( $CAH ), SEI Investments( $SEIC ), WEC Energy( $WEC ) and Host Hotels( $HST ) https://lnkd.in/gCkRQBHF #correlations #stocks #stockratings

Estimating Root (USA Stocks:ROOT) price for December 2024.: High risk, high reward often defines the journey of investing in stocks like Root Inc. As we look towards December 2024, Root Inc. (NASDAQ: ROOT) presents a complex picture for investors. Despite its current 52-week high of 86.57, the stock's forecasted value of 38.37 suggests a significant potential downside, especially when coupled with a Price Action Indicator of -8.3. The company's financial health raises eyebrows, with expected earnings per share for the next year at a loss of 2.33. The insurance sector's volatility, reflected in Root's high beta of 2.534, further complicates the outlook. While analysts have a consensus of buy, with two strong buy recommendations, caution is advised given the short interest ratio of 7.05, indicating a substantial amount of skepticism in the market. For those considering a stake in Root, it's crucial to weigh these factors carefully against your risk tolerance and investment strategy. Currently, Root's income quality is more stable than it was last year. By 2024, the company's EV to Operating Cash Flow is expected to rise to 7.17, while the Free Cash Flow Yield might decrease to -0.30. This analysis aims to provide private investors with insights into Root's potential future value. We'll explore why this could be significant for those investing in Root.Continue To Read... https://lnkd.in/gUhZp4yh

Will Tharimmune (USA Stocks:THAR) turn things around in December?: Every cloud has a silver lining, and for Tharimmune (NASDAQ: THAR), December might just be the month to shine. Despite a challenging year marked by a net income loss of 9.3 million, the biotechnology company is poised for a potential rebound. With its stock currently hovering around a typical price of $4.30, analysts have set their sights on a target price range between $3.64 and $4.44. This suggests a cautious optimism for investors willing to bet on a turnaround. While the return on equity stands at a disappointing loss of 1.82, the company's focus on innovative solutions in the pharmaceuticals and life sciences sector could be the catalyst needed for a comeback. As the year draws to a close, Tharimmune's resilience in the healthcare arena might just surprise the skeptics. Tharimmune's current ratio has remained relatively stable over the past year. By October 31, 2024, the tangible book value per share is expected to rise to $7.34, while the operating cash flow per share might decrease to $5.87. With more conservative investors showing interest in the biotechnology sector, Tharimmune could be worth considering. What can shareholders expect in December? In this discussion, I'll explore several factors influencing Tharimmune's products and services and how these might affect retail investors.Continue To Read... https://lnkd.in/gP7MtTxD

Risk-adjusted landscape for Mosaic( $MOS ), Textron( $TXT ), Peabody Energy( $BTU ), PPL( $PPL ), Prudential Financial( $PRU ), Kimco Realty( $KIM ), Texas Instruments( $TXN ), Electronic Arts( $EA ) and Mentor Capital( $MNTR ) https://lnkd.in/gDdKN7Tn #correlations #stocks #stockratings

Will Monte Rosa continue to dip in December?: Monte Rosa Therapeutics has $46.04 million in liabilities and a Debt to Equity (D/E) ratio of 0.16, indicating limited use of borrowing. With a current ratio of 19.71, the company is well-positioned to meet its financial obligations. When evaluating Monte Rosa's debt, it's important to consider its cash and equity positions. The company has a performance score of 11 out of 100 and a Beta of 5.01, suggesting high market risk. This means it could outperform in a rising market but may underperform if the market declines. To assess potential returns, consider using metrics like the Sortino ratio, skewness, period momentum indicator, and the relationship between potential upside and rate of daily change. Key Discoveries Monte Rosa Therapeutics' stock exhibits significant volatility, as highlighted by its Coefficient of Variation of 771.99, suggesting that price swings are substantial and could lead to unpredictable movements. With a Maximum Drawdown of 95.03, the stock has experienced severe declines, indicating that while a rebound is possible, investors should brace for potential further declines in December.Continue To Read... https://lnkd.in/gijkWP7p

Are Upexi (USA Stocks:UPXI) traders starting to hold back?: In the stock market, momentum can be a powerful ally. Upexi Inc. has recently seen a significant upswing, climbing over 27%, which has piqued the interest of investors. Despite this surge, it's crucial to weigh the company's fundamentals before jumping on the bandwagon. Upexi operates in the Internet Content & Information sector, with a current market valuation of $8.55 million. However, its financials tell a more cautious story, with an EPS estimate for the current year showing a loss of 9.8 and next year's forecast not looking much brighter at a loss of 6.8. The stock's 52-week high of $33 suggests potential, but with a Wall Street target price of $25, there's a need for careful consideration. The analyst consensus currently stands at 'Hold,' indicating that while there is room for growth, it may be prudent to watch for further developments before making a move. Upexi Inc's cash per share has been on the rise compared to past years, which is a positive sign for investors. Currently, the company's price-to-cash-flow ratio is expected to climb to 1,469, while the price-to-sales ratio is anticipated to drop to 10.89. This report aims to provide traders with our insights on Upexi for November, offering a forecast to help guide investment decisions.Continue To Read... https://lnkd.in/gWvqe8y4

Very bullish portfolio: Cincinnati Financial( $CINF ), Fifth Third( $FITB ), Nucor Corp( $NUE ), Autodesk( $ADSK ), Marsh McLennan( $MMC ), Costco Wholesale( $COST ) and Xtrackers California( $CA ) https://lnkd.in/gQFGYjzV #correlations #stocks #stockratings

Build optimal portfolios with Southwest Airlines( $LUV ), NOV( $NOV ), Amazon( $AMZN ), T Rowe( $TROW ), Boston Properties( $BXP ), Xtrackers California( $CA ) and Thermo Fisher( $TMO ) https://lnkd.in/gcTAAZ_J #correlations #stocks #stockratings

Will Monopar Therapeutics (USA Stocks:MNPR) continue to fall in November?: Three analysts have given Monopar Therapeutics a "Strong Buy" rating. But what does this mean? Analysts don't just rely on technical analysis, which involves studying price momentum, patterns, and trends from past data to gauge market sentiment and predict future movements. Instead, their recommendations often combine both technical and fundamental analysis, considering factors like the company's financial health, product pipeline, and market conditions. While technical analysis can provide insights into investor sentiment, it's just one piece of the puzzle. Let's explore some key elements of Monopar's technical analysis to understand how it might influence investor decisions. Key Takeaways Monopar Therapeutics (NASDAQ: MNPR) has been catching attention with its recent news, but a closer look at the technical indicators suggests a more cautious approach. The stock's Coefficient of Variation stands at a high 819.18, indicating significant volatility and potential risk for traders. Despite a Wall Street target price of 18, which suggests a potential upside of 15.92%, the current price percent change of -9.09% signals that the stock is experiencing downward pressure. Additionally, with an operating income loss of 8.8M, investors should weigh these technical factors carefully before making any trading decisions.Continue To Read... https://lnkd.in/gikjQrkc